Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesLisata Therapeutics

Lisata Therapeutics

PortfolioPortfolio WatchlistWatchlist
Company price
1.02 GBX 0.02 ( 2.50%)
Last update at 2026-10-27T16:45:00Z
VOLUME
68
Market Cap
0.00M

Momentum Score

…

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.02
Low
1.02
High
52 Week Price Range
1.88
Low
5.10
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
1.00
Dividend Yield
-
Revenue TTM
0.17M
Revenue Per Share
0.02
Gross Profit TTM
0.17M
Debt / Equity
-
ROE
-75.53%
Net Debt
-
ROCE
-89.40%
Diluted EPS TTM
-0.39

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Income before tax - -19.01M -19.35M -16.17M -27.70M
Minority interest - -0.25M -0.26M -0.27M -0.32M
Net income - -8.15M -19.36M -16.17M 22.98M
Selling general administrative - 9.89M 9.29M 9.39M 11.75M
Ebit -29.05M -19.14M -20.09M -16.99M -27.59M
Operating income - -19.14M -20.09M -16.99M -27.59M
Interest expense 0.00M 0.00M 0.00M 0.00M 0.00M
Tax provision - -10.87M - - -11.53M
Interest income - - - 0.01M 0.38M
Extraordinary items - - - - 38.97M
Income tax expense -1.51M -10.87M - - -11.53M
Discontinued operations - - - - 38.97M
Net income applicable to common shares -27.47M -8.15M -19.36M -16.17M 22.98M
Breakdown 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Total assets - 36.00M 27.15M 44.58M 63.38M
Other current assets - - - - 5.00M
Total liab - 3.51M 6.34M 6.85M 12.87M
Total stockholder equity - 32.50M 20.82M 37.73M 50.51M
Other current liab - - 1.60M 2.58M 4.68M
Common stock 0.06M 0.02M 0.01M 0.01M 0.01M
Retained earnings -453.02M -425.55M -417.40M -397.98M -381.81M
Other liab 0.48M - 0.62M 1.51M 3.87M
Other assets 0.04M 0.04M 0.17M 0.31M 1.72M
Cash - 16.51M 14.03M 10.30M 29.16M
Total current liabilities 4.52M 3.51M 5.98M 5.62M 9.31M
Other stockholder equity -0.07M -0.01M 0.00M -0.03M -0.03M
Property plant equipment 0.79M 0.63M 1.01M 0.17M 0.26M
Total current assets 96.18M 35.33M 25.97M 44.11M 61.40M
Net tangible assets 92.25M 32.50M 20.82M 37.73M 50.51M
Short term investments - 18.06M 11.12M 32.75M 25.92M
Net receivables - - - - 0.23M
Accounts payable 1.93M 1.02M 1.49M 0.76M 1.34M
Treasury stock - -0.71M -0.71M -0.71M -0.71M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments - - - -54.84M -7.26M
Change to liabilities - - - 1.25M -2.84M
Total cashflows from investing activities - - - -54.90M -7.28M
Total cash from financing activities - - - 85.28M 18.58M
Change to operating activities - - - -0.60M 0.52M
Net income -19.98M -20.84M -54.23M -27.47M -8.15M
Change in cash - - - 8.13M 2.48M
Total cash from operating activities - - - -22.25M -8.82M
Depreciation - - - 0.06M 0.06M
Other cashflows from investing activities - - - - -7.26M
Sale purchase of stock - - - - 18.73M
Other cashflows from financing activities - - - - -0.15M
Change to netincome - - - 4.52M 1.58M
Capital expenditures 0.00M 0.00M 0.00M 0.06M 0.02M
Change in working capital - - - - -2.32M

Peer Comparison*

Sector: Industry:

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
0HS8
Lisata Therapeutics		 0.02
2.50%		 1.02 - - - -
0R15
SoftBank Group Corp.		 248.00
5.84%		 4494.00 - - - -
0R1E
Nintendo Co. Ltd.		 -115.00
1.34%		 8476.00 - - - -
0LC3
Synchrony Financial		 2.34
3.20%		 75.60 0.09 - 4.97 -
0HQP
CBRE Group Inc. Cl A		 0.15
0.12%		 122.47 0.25 - 1.18 -

Profile*

Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

110 Allen Road, Basking Ridge, NJ, United States, 07920

908 842 0100

https://www.lisata.com

21

Name Title Year Born
Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. CEO & Director 1957
Dr. Kristen K. Buck M.D. Exec. VP of R&D and Chief Medical Officer 1974
Mr. David Slack MBA Pres, Chief Bus. Officer & Director 1963
Mr. James Nisco VP of Fin. & Treasury NA
Mr. Gregory S. Berkin Chief Information Officer NA
Mr. John D. Menditto VP of Investor Relations & Corp. Communications NA
Eric Powers Director of Communications and Marketing NA
Ms. Gail Holler VP of HR 1959
Dr. Ian Zhang MBA, Ph.D. Pres of NeoStem (China), Inc and Managing Director of NeoStem (China), Inc 1965
Dr. William K. Sietsema Ph.D. VP of Global Regulatory Affairs 1956

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…